15-year follow-up of recurrent "hypoglycemia" in preterm infants

Win Tin1, Greta Brunskill, Tom Kelly

  • 1Department of Neonatal Medicine, James Cook University Hospital, Middlesbrough, United Kingdom. win.tin@stees.nhs.uk

Pediatrics
|November 7, 2012
PubMed

Insights

Recurrent low blood glucose levels in preterm infants do not appear to cause long-term harm. This study found no significant differences in development or cognitive function in children with early hypoglycemia compared to controls.

Area of Science:

  • Neonatal care
  • Pediatric neurology
  • Developmental pediatrics

Background:

  • A 1988 study suggested recurrent hypoglycemia in preterm infants (<1850g) led to impaired development.
  • This prior observation lacked replication and its clinical significance remained uncertain.

Purpose of the Study:

  • To investigate the long-term neurodevelopmental outcomes of preterm infants with recurrent asymptomatic hypoglycemia.
  • To determine if early low blood glucose levels pose a developmental hazard in a contemporary cohort.

Main Methods:

  • A cohort of infants born before 32 weeks gestation in the north of England (1990-1991) had daily blood glucose monitoring for 10 days.
  • Children with recurrent hypoglycemia (≤2.5 mmol/L on ≥3 days) were compared to matched controls at ages 2 and 15 years.

Main Results:

  • No significant differences in physical disability or developmental progress were found at age 2.
  • At age 15, psychometric assessments showed nearly identical cognitive function (mean full-scale IQ: 80.7 vs 81.2) between the hypoglycemia group and controls.
  • Subgroup analyses with more frequent or lower glucose thresholds did not alter these findings.

Conclusions:

  • This study provides no evidence that recurrent low blood glucose levels (≤2.5 mmol/L) in the first 10 days of life are a hazard to preterm infants.
  • The findings challenge previous concerns about the long-term impact of asymptomatic neonatal hypoglycemia.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...